CORNWALL, England and MALVERN, Pa., June 1 /PRNewswire/ -- Key Organics Ltd (“Key”) and Reaction Biology Corporation (“RBC”) today announced that they have teamed up to provide a new library screening format to customers. Beginning this summer, the entire Key Bionet library of 37,500 diverse drug-like compounds will be offered for “rental” screening on RBC’s DiscoveryDot(TM) platform. For the first time, customers will be able to screen the Key library without having to purchase it outright.
“While we have many large pharma clients who wish to purchase compounds directly, we see an unmet need in smaller pharma and biotech companies that want to screen one or more of their targets without investing in a library purchase,” said Colin Piper, Business Development Manager for Key. “RBC’s platform gave us an economical way to reach these potential customers. Now researchers who do not have a budget for library purchases can still afford library screening.”
The Key library will be screened locally at RBC’s lab facilities in Malvern, PA. RBC will reformat the library to its microarray-based platform. “Our nanoliter-scale screening process means that we can we offer lower costs to customers, while our partnership with Key provides a clear path to additional chemistry expansion,” said Tom Festa, National Sales Manager for RBC.
*(LOGO: Send2Press.com/mediadesk/logo-reactionbio_72dpi.jpg)
About Reaction Biology Corporation
Reaction Biology, based in Malvern, Pa., provides high throughput screening services to the biotechnology and pharmaceutical industries. The company uses a patent-pending combination of technologies to perform screening at the nanoliter scale, while preserving quality, speed and simplicity. Combining genomics microarray printing technology and picoliter aerosol deposition, RBC has commercialized a novel technology that drives HTS to new levels of simplicity and efficiency. www.reactionbiology.com
*(LOGO: Send2Press.com/mediadesk/logo-keyorganics_72dpi.jpg)
About Key Organics Ltd.
Key Organics Limited was formed in 1986 to supply schemes of novel, benzenoid and heterocyclic chemistry to its customers under confidentially agreements. During Key’s growth over the last 20 years, custom and contract synthesis and lead optimisation programmes for clients worldwide have become an increasingly important part of its business. The Company is based at its own well-equipped multi-lab site in Camelford, Cornwall, UK. Key Organics employs Graduate and Ph.D. chemists, including medicinal chemists, with experience in a wide range of chemical techniques and technologies. Key Organics is able to supply mg to kg quantities of compounds to a high specification. www.keyorganics.ltd.uk
This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com
Key Organics Ltd; Reaction Biology Corporation
CONTACT: Tom Festa, National Sales Manager of Reaction BiologyCorporation, +1-908-581-6154, or fax, +1-908-781-0836,tom@reactionbiology.com; or Dr. Colin Piper, Business Development Managerof Key Organics Ltd., +44 (0) 1840 212137, +44 (0) 1840 213712,colinp@keyorganics.ltd.uk
